Profile data is unavailable for this security.
About the company
AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing its botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection or ABP-450, for debilitating medical conditions, with an initial focus on the neuroscience market. ABP-450 is a 2-chain polypeptide, a heavy chain joined by a bond to a light chain. ABP-450 interferes with nerve impulses by inhibiting the release of acetylcholine into the neuromuscular junction, causing a flaccid paralysis of muscles. The active biologic ingredient in ABP-450 is Clostridium botulinum toxin, type A with a complete molecular complex weight of 900 kDa. Its initial development programs for ABP-450 are directed at migraine, cervical dystonia, gastroparesis and post-traumatic stress disorder (PTSD). The Company has completed a Phase II study of ABP-450 for the treatment of cervical dystonia and are conducting a Phase II study of ABP-450 for the treatment of both chronic and episodic migraine.
- Revenue in USD (TTM)0.00
- Net income in USD-485.01m
- Incorporated2020
- Employees10.00
- LocationAeon Biopharma Inc5 Park Plaza, Suite 1750IRVINE 92614United StatesUSA
- Phone+1 (949) 354-6499
- Fax+1 (302) 655-5049
- Websitehttps://aeonbiopharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cidara Therapeutics Inc | 46.38m | -36.47m | 93.19m | 69.00 | -- | -- | -- | 2.01 | -8.07 | -8.07 | 10.26 | -3.90 | 0.6899 | -- | 2.80 | 672,144.90 | -54.24 | -65.23 | -218.59 | -154.37 | 76.93 | -- | -78.63 | -100.61 | 0.6047 | -- | -- | -- | -0.8425 | -- | 31.72 | -- | 23.33 | -- |
| Hillevax Inc | 0.00 | -143.51m | 93.97m | 90.00 | -- | 0.3881 | -- | -- | -3.29 | -3.29 | 0.00 | 4.87 | 0.00 | -- | -- | 0.00 | -46.66 | -- | -50.34 | -- | -- | -- | -- | -- | -- | -- | 0.0963 | -- | -- | -- | 22.68 | -- | -- | -- |
| Checkpoint Therapeutics Inc | 68.00k | -52.32m | 94.87m | 23.00 | -- | -- | -- | 1,395.22 | -2.37 | -2.37 | 0.0028 | -0.2872 | 0.0076 | -- | -- | 2,956.52 | -585.51 | -142.43 | -- | -342.79 | -- | -- | -76,938.23 | -6,554.97 | -- | -- | -- | -- | -46.35 | -50.61 | 17.21 | -- | -- | -- |
| Cognition Therapeutics Inc | 0.00 | -28.77m | 94.94m | 25.00 | -- | 3.28 | -- | -- | -0.9155 | -0.9155 | 0.00 | 0.7218 | 0.00 | -- | -- | 0.00 | -68.08 | -- | -85.18 | -- | -- | -- | -- | -- | -- | -251.59 | 0.00 | -- | -- | -- | -20.52 | -- | -- | -- |
| Anixa Biosciences Inc | 0.00 | -11.60m | 97.62m | 4.00 | -- | 4.13 | -- | -- | -0.3694 | -0.3694 | 0.00 | 0.7381 | 0.00 | -- | -- | 0.00 | -45.19 | -59.69 | -46.33 | -62.61 | -- | -- | -- | -6,040.10 | -- | -- | 0.00 | -- | -- | -28.36 | 27.83 | -- | -- | -- |
| Aclaris Therapeutics Inc | 31.12m | -77.26m | 99.06m | 91.00 | -- | 0.6974 | -- | 3.18 | -1.09 | -1.09 | 0.4392 | 1.99 | 0.1541 | -- | 58.77 | 341,967.00 | -38.27 | -47.29 | -42.29 | -53.87 | 41.99 | 44.00 | -248.28 | -549.18 | -- | -- | 0.00 | -- | 5.03 | 38.41 | -1.81 | -- | -0.703 | -- |
| Vistagen Therapeutics Inc | 1.06m | -29.36m | 99.56m | 39.00 | -- | 0.8702 | -- | 93.57 | -2.12 | -2.12 | 0.055 | 4.23 | 0.0147 | -- | -- | 27,282.05 | -40.57 | -62.84 | -43.48 | -68.03 | -- | -- | -2,759.59 | -5,768.52 | -- | -- | 0.00 | -- | 568.10 | -- | 50.44 | -- | -18.91 | -- |
| Tiziana Life Sciences Ltd - ADR | 0.00 | -15.40m | 102.06m | 9.00 | -- | 5.17 | -- | -- | -0.1496 | -0.1496 | 0.00 | 0.1914 | 0.00 | -- | -- | 0.00 | -40.89 | -- | -50.40 | -- | -- | -- | -- | -- | -- | -2,083.71 | 0.0183 | -- | -- | -- | 34.25 | -- | -- | -- |
| Aeon Biopharma Inc | 0.00 | -485.01m | 102.89m | 10.00 | -- | -- | -- | -- | -13.04 | -13.04 | 0.00 | -5.20 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -27.67 | -- | -- | -- | -- | -631.85 | -- | -- | -- |
| Cardiff Oncology Inc | 610.00k | -40.25m | 104.66m | 31.00 | -- | 1.72 | -- | 171.57 | -0.901 | -0.901 | 0.0137 | 1.36 | 0.0068 | -- | 1.14 | 19,677.42 | -44.55 | -31.24 | -50.10 | -33.56 | -- | -- | -6,594.92 | -7,819.23 | -- | -- | 0.00 | -- | 26.42 | 5.22 | -7.07 | -- | 157.91 | -- |
| Armata Pharmaceuticals Inc | 4.70m | -79.58m | 105.21m | 66.00 | -- | -- | -- | 22.39 | -2.20 | -2.20 | 0.1302 | -1.56 | 0.041 | -- | 3.16 | 71,196.97 | -69.46 | -59.78 | -235.17 | -72.70 | -- | -- | -1,693.47 | -1,113.72 | -- | -1.11 | 1.75 | -- | -17.77 | -- | -87.03 | -- | 184.10 | -- |
| Oramed Pharmaceuticals, Inc. | 674.00k | 10.46m | 105.64m | 15.00 | 10.45 | 0.6322 | 10.11 | 156.73 | 0.2488 | 0.2488 | 0.0165 | 4.11 | 0.0037 | -- | -- | 44,933.33 | 5.63 | -- | 6.27 | -- | -- | -- | 1,518.25 | -- | -- | -- | 0.162 | -- | -50.43 | -- | 115.11 | -- | -- | -- |
| Omega Therapeutics Inc | 4.94m | -92.28m | 105.90m | 93.00 | -- | 2.56 | -- | 21.44 | -1.67 | -1.67 | 0.0896 | 0.7498 | 0.029 | -- | 6.08 | 53,107.53 | -54.28 | -- | -62.10 | -- | -- | -- | -1,868.35 | -- | -- | -- | 0.302 | -- | 49.25 | -- | 5.13 | -- | -- | -- |
| Sagimet Biosciences Inc | 2.00m | -27.92m | 109.15m | 10.00 | -- | 0.5744 | -- | 54.57 | -1.23 | -1.23 | 0.0862 | 5.95 | 0.018 | -- | -- | 200,000.00 | -25.18 | -- | -26.34 | -- | -- | -- | -1,395.90 | -- | -- | -- | 0.00 | -- | -- | -- | 8.60 | -- | -- | -- |
| Coya Therapeutics Inc | 6.13m | -10.30m | 111.88m | 8.00 | -- | 3.32 | -- | 18.25 | -0.8899 | -0.8899 | 0.5401 | 2.22 | 0.2236 | -- | -- | 766,131.30 | -37.59 | -- | -41.86 | -- | -- | -- | -168.11 | -- | -- | -- | 0.00 | -- | -- | -- | 34.77 | -- | -- | -- |
Data as of Jul 26 2024. Currency figures normalised to Aeon Biopharma Inc's reporting currency: US Dollar USD
14.12%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Polar Asset Management Partners, Inc.as of 31 Mar 2024 | 3.68m | 9.39% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 751.75k | 1.92% |
| Ikarian Capital LLCas of 31 Mar 2024 | 257.98k | 0.66% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 247.92k | 0.63% |
| Geode Capital Management LLCas of 31 Mar 2024 | 179.60k | 0.46% |
| Goldman Sachs & Co. LLC (Private Banking)as of 31 Mar 2024 | 169.16k | 0.43% |
| Formidable Asset Management LLCas of 31 Mar 2024 | 68.19k | 0.17% |
| Qube Research & Technologies Ltd.as of 31 Mar 2024 | 59.82k | 0.15% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 59.55k | 0.15% |
| Millennium Management LLCas of 31 Mar 2024 | 55.99k | 0.14% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
